Dengvaxia is the world's first dengue vaccine developed by Sanofi Pasteur. It is designed to protect against the four serotypes of the dengue virus (DENV 1, 2, 3, and 4). The vaccine is a live attenuated recombinant tetravalent vaccine, which means it contains weakened forms of the virus that cannot cause disease but can stimulate an immune response.
